[Evaluation of the DIABOBHU Observational Study]

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacotherapy

Background:

• DIABOBHU observational study analyzed outcomes in Hungarian type 2 diabetes patients with inadequate oral antidiabetic agent treatment.
• Focus on patients requiring intensified glycemic management beyond oral agents.

Purpose of the Study:

• Evaluate the safety and efficacy of adding glargine insulin to existing oral antidiabetic therapy.
• Assess glycemic control, patient weight, and hypoglycemia incidence.

Main Methods:

• 3955 type 2 diabetes patients enrolled between 2008-2011.
• 26-week study with patient education, physician-guided insulin titration, and self-monitoring.
• Primary endpoint: HbA1c change; Secondary endpoints: fasting glucose, insulin dose, body weight, BMI, patient satisfaction, hypoglycemia events.

Main Results:

• Mean HbA1c decreased significantly from 8.94% to 7.31%.
• Glycemic goals were achieved by most patients with a very low incidence of hypoglycemia.
• No significant weight gain was observed, and patient satisfaction was high.

Conclusions:

• Glargine insulin, as an analogue basal insulin, offers an effective and safe therapeutic option.
• This treatment strategy is recommended for type 2 diabetes patients inadequately controlled by oral agents.